Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.
In this segment of the video discussion focused on hepatocellular carcinoma (HCC), Kim and the panel of medical experts delved into the complexities of health care resource utilization and associated costs in HCC treatment strategies. The multidisciplinary nature of HCC treatment was emphasized, with discussions on the involvement of various specialists such as medical oncologists, hepatologists, and the need for comprehensive care in tertiary centers. The significance of preventing liver cirrhosis, hepatitis B, and hepatitis C was underscored as a potential cost-saving measure, with the panel advocating for the integration of preventive strategies such as vaccination and antiviral therapies to curtail the progression of HCC.
The conversation expanded to the interplay between value-based care principles and health care resource utilization. Kim shed light on the significance of striking a balance between effective treatment outcomes and managing the costs and resource utilization associated with HCC therapies. The experts stressed the importance of considering the burden on the patient and the potential impact on their quality of life when evaluating treatment options, underlining the need for patient-centric approaches in HCC management.
Furthermore, the panel emphasized the judicious use of diagnostic procedures and imaging studies, cautioning against overreliance on sophisticated imaging techniques when clinical examinations could suffice. They advocated for a streamlined and pragmatic approach to diagnostic processes to avoid unnecessary radiation exposure and minimize health care costs without compromising the quality of patient care. The experts urged health care providers to adhere to standardized practices and minimize redundant tests, emphasizing the need to optimize the use of health care resources for the benefit of HCC patients.
Throughout the discussion, the experts’ insights reflected a comprehensive understanding of the challenges and opportunities in HCC treatment, underscoring the importance of preventive measures, cost-effectiveness, and patient well-being. Their discourse provided valuable guidance for health care practitioners and policymakers alike, seeking to optimize HCC treatment strategies while efficiently utilizing health care resources.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More